Skip to content
‹ Back to IndustriesSciences

Peptide drug runs can stall on late raw materials, Frost & Sullivan and Medtide find

Frost & Sullivan and Medtide's 2026 white paper on peptide and oligonucleotide drugs ties contract manufacturer selection to program stage. Its sharpest point is that a late resin, amino acid or nucleotide building block can stall a campaign even with plant capacity free. Supplier depth belongs in CDMO qualification.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By MarketScale Newsroom · Frost & SullivanMedtidePeptide ManufacturingOligonucleotide Manufacturing
Share
Peptide drug runs can stall on late raw materials, Frost & Sullivan and Medtide find

Key takeaways

01

Open capacity at a contract manufacturer means little if a nonstandard amino acid or a modified nucleotide building block arrives late, so the supplier list deserves the same scrutiny as the capacity reservation.

02

What makes a good CDMO changes as a program matures: speed of problem solving decides early clinical timelines, while proven scale-up, raw-material access, reserved capacity and site-to-site transfer decide launch readiness.

03

A useful question for any prospective partner is which critical inputs for a given molecule already have a second qualified supplier, because switching sources later can trigger extra quality testing.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

A drug manufacturing campaign can stall with plant capacity sitting open, just because a specialized resin or a modified nucleotide building block shows up late. That's one of the most practical warnings in the 2026 Global Peptide and Oligonucleotide Drug Industry White Paper. Frost & Sullivan, a global growth consulting firm, and Medtide Inc. jointly released the report on November 20, 2026. Medtide Inc. (HKEX: 03880.HK) specializes in peptides and oligonucleotides as a contract research, development and manufacturing organization (CRDMO). It runs operations in China and the United States through two entities, Chinese Peptide Company and CPC Scientific, Inc.

The paper covers the market for these two drug families, together called TIDES, through 2030. To judge where demand is growing and which therapies could shape the market, it reviews approved products and late-stage pipelines worldwide. Its most useful part is a stage-by-stage account of what drugmakers should demand from contract development and manufacturing organizations (CDMOs). For the external manufacturing lead deciding which partner carries a molecule from clinic to launch, the useful question is what to check, and at which point in the program.

Peptides and oligos break at different points

Peptides face pressure on volume. According to the white paper, much of the recent rise in peptide sales comes from demand for GLP-1 therapies. The paper ties broad use of those therapies for diabetes and obesity to greater demand for peptide active ingredients, and that makes large-scale synthesis and purification the top priority. The difficult part is increasing output while keeping purity and yield intact.

Solid-phase synthesis is the workhorse. Liquid-phase synthesis and fragment condensation fit certain molecules, and as peptide structures get more complex, the choice of route and purification process can materially change how much usable product comes out of each batch.

Oligonucleotides face a different problem. The paper says improved delivery technology is moving development past rare diseases and into common cardiovascular and metabolic conditions, and that means larger batches. Synthesis can create impurities that closely resemble the intended sequence, which makes them difficult to detect and difficult to remove. The paper ties that challenge to the move into late-stage trials, when developers need reliable ways to identify closely related impurities and hold quality steady across larger batches. So the detection problem and the scale problem tend to show up at the same time.

Depending on the product, a manufacturer may also need to join two strands together, conjugate a targeting molecule like GalNAc, or package the drug in lipid nanoparticles. Each of those steps requires analytical methods that can still confirm identity and consistent quality at commercial scale.

Taken together, this suggests the first question should differ by molecule. For a peptide partner, ask about yield and purification throughput on structures as complex as yours. For an oligonucleotide partner, the analytical package may matter more than raw synthesis volume, because it decides whether the impurity profile can be shown to stay stable as batches grow.

Depending on the product, oligonucleotide manufacturers may also need to attach a targeting molecule such as GalNAc. Each extra step like that could mean another process to validate and another material to source as a program scales.

The supplier list is part of capacity

Peptide makers rely on inputs such as nonstandard amino acids and resins. Oligonucleotide makers may need modified nucleotide building blocks or conjugation materials that only a small number of qualified suppliers provide. The white paper notes that changing suppliers can require extra testing to show the switch doesn't affect product quality. A backup supplier only helps if it was qualified before anyone needed it. For programs that rely on those specialty inputs, supplier qualification should probably start during development rather than wait until the launch campaign is on the calendar.

Even when production capacity is available, a late specialized raw material can throw a manufacturing campaign off course. For drugmakers, that suggests a CDMO's supplier list deserves the same scrutiny as its capacity reservation. The paper describes how manufacturers manage the risk: they qualify alternative suppliers in advance, hold inventory of long-lead materials and reserve capacity for late-stage programs. It also looks at when regional manufacturing networks can keep supply moving if trade or logistics problems hit a single site or supplier.

A backup supplier only helps if it was qualified before anyone needed it.

Switching costs come down to analytics. In its section on quality, the paper says manufacturers must know three things: the impurities their process is capable of producing, how dependably their methods catch those impurities, and whether changing the process shifts the impurity profile. Moving a resin or building block to a new source is that kind of change. How strong a partner's analytical methods are could therefore determine how much testing follows a supplier swap. That bar could be harder to clear for oligonucleotides, because their impurities look very much like the intended sequence.

What changes as launch gets closer

In early development, the paper argues, the speed at which a partner solves problems can determine how quickly a program reaches its next clinical milestone. At this point a CDMO may help select a workable manufacturing route, build analytical methods and supply trial material, so issues are found before they get harder to fix at volume.

Closer to launch, the priorities shift to a proven record of scaling up, secure access to critical raw materials and the option to reserve capacity for commercial production. At that stage the paper says drugmakers need a partner that can validate the process and deliver batches that consistently meet specifications. Here the supplier question from the previous section becomes concrete. Raw-material access sits on the paper's list of late-stage priorities right next to capacity.

Launches in several markets add two more factors: experience supporting regulatory filings and transferring production between sites. The paper reviews quality expectations in the United States, Europe and China, including China's continued alignment with international standards. It also emphasizes consistent quality systems, traceable data and documented change control.

The white paper lays out a framework drugmakers can apply when qualifying a CDMO and judging whether it fits a long-term partnership:

  1. Initial qualification: good manufacturing practice (GMP), analytical capabilities and experience with comparable molecules.
  2. Approaching launch: proof of successful scale-up and technology transfer, plus reliable delivery at the needed volume.
  3. Before a long-term agreement: the way a CDMO reports quality deviations, how it communicates production schedule changes and how it assigns responsibility for fixing supply interruptions.

The third layer is the one most likely to get skipped, since it describes how the relationship behaves when something goes wrong, and that rarely comes up in a capability audit. Agreeing on it before a long-term contract gives both sides a shared playbook for the moment a batch slips.

Sponsors should be careful not to lean too heavily on the paper's map of providers when they decide what to buy. Among the leading names it highlights are Bachem, ST Pharm, WuXi AppTec, Nitto Avecia, PolyPeptide, CordenPharma, Agilent and Medtide. The comparison places specialist manufacturers alongside broader service providers and companies entering TIDES from adjacent businesses. It assesses each company on the molecules it supports, the span of its services from process development through commercial production, and the locations where it can make and supply products.

Those dimensions roughly track the framework's stages. Molecule coverage bears on initial qualification, service span on scale-up and transfer, and manufacturing footprint on multi-market supply. Medtide is a joint publisher of the paper and also one of the providers it features. The company says it has served more than 1,000 clients, with projects in more than 50 countries and regions. The map works best for orientation. To test any of those providers against its own molecule, a sponsor can use the framework above.

Ask a prospective CDMO which critical inputs for your molecule already have a second qualified supplier, and what quality testing a switch would trigger. The answer shows how exposed the launch is better than a capacity figure does.

Continuous purification today, continuous plants later

The report draws a line between technology already in use and technology still on the way. Automation of individual synthesis steps, continuous purification and digital batch records that trace production and quality data are already being adopted by manufacturers. Fully continuous manufacturing from start to finish is still in development, and companies are still testing whether AI can help optimize processes and predict batch outcomes.

The paper also notes that providers are investing in purification capacity. That fits its own diagnosis. Purification is where peptide yield and oligonucleotide impurity removal both run into trouble at scale, which suggests it is the step where added capacity is most likely to show up as usable output.

Solvent is the other cost of scale. Synthesis and purification can both use large volumes of it, and the paper looks at solvent recovery, waste treatment and alternative processes as ways to cut material use and disposal burden as output grows. For a sponsor drafting a supply agreement now, digital batch records and continuous purification are capabilities worth asking for by name. End-to-end continuous manufacturing belongs in roadmap conversations until a provider can show it running at commercial scale.

Featured companies

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

MarketScale Newsroom
MarketScale NewsroomEditorial Team, MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Merck's $550 million lab was built for robots whose specs weren't final

Merck's $550 million lab was built for robots whose specs weren't final

Merck's $550 million ADVANCE lab in West Point, Pennsylvania, which opened in October 2026, reserved floor space for robots before some of them had final dimensions. Containment sits inside robotic work cells, space and utilities were sized for the largest expected machines, and validation waited until construction ended. Other lab capital projects can reuse that order of work.

  • 01When robotic platforms carry their own enclosures, walls are needed mainly where the science or access control demands them, and the open floor plan is designed to make future equipment swaps easier without automatically forcing new room build-outs.
  • 02Merck planned for the largest expected robot sizes and highest utility needs, using lessons from its 2023 Spring House lab, according to Lab Design News. Teams without a previous project to learn from could find those limits harder to set.

Nov 21, 2026

Keller’s case for carbs as key fuel for post-workout muscle repair

Keller’s case for carbs as key fuel for post-workout muscle repair

In a NuLiv Science segment, nutrition scientist and dietitian Dr. Rosa Keller argues that carbohydrate (glucose) is a key fuel for mitochondrial ATP after resistance training and that clients often under-eat carbs. The article cites reviews emphasizing carbohydrate for glycogen restoration (including John Ivy’s 1.2 g/kg/hour post-exercise target), describes protein as a co-ingested partner in recovery, and notes ketogenic-diet findings that may benefit aging mitochondria.

  • 01John Ivy's post-exercise carbohydrate target is about 1.2 grams per kilogram of body weight per hour, taken early and often, to maximize glycogen resynthesis.
  • 02Nature Metabolism describes carbohydrate as the primary fuel for ATP in most Olympic events, and Keller argues that post-exercise repair depends on mitochondria having fuel to generate ATP.
  • 03Ketogenic diets improve muscle mitochondrial mass and function with age or disease but not in athletes, Pathak and Baar concluded, so the carbohydrate rule depends on who is training.

Nov 20, 2026

Lab Thread's MCP server lets scientists ask their own AI assistant about lab records

Lab Thread's MCP server lets scientists ask their own AI assistant about lab records

Lab Thread has launched a Model Context Protocol server that lets scientists query their lab records from ChatGPT, Claude or other AI assistants. The server runs inside Lab Thread's cloud with audit logs aligned to 21 CFR Part 11, so the audit trail stays with the record system. The company also opened a Boston office.

  • 01For a regulated lab, the useful question about any AI connector is where the audit log lives. Lab Thread keeps it inside its own tenant-isolated cloud and shares only the minimum context each authorized query needs.
  • 02Pinning an MCP server version doesn’t lock its transitive dependencies, so the code that runs can still change between builds. If Lab Thread’s MCP server is vendor-hosted in its secure cloud, the local install/package chain would be the vendor’s to manage rather than something each scientist launches on a laptop.
  • 03Before connecting an assistant, ask what the audit log records for each AI query: the user, the records touched and the context sent outside the platform.

Nov 20, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

MarketScale Newsroom
MarketScale Newsroom

Editorial Team

MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512